TY - JOUR
T1 - Efficacy and safety of beloranib for weight loss in obese adults: A randomized controlled trial
AU - Kim, D.D.
AU - Krishnarajah, J.
AU - Lillioja, S.
AU - De Looze, F.
AU - Marjason, J.
AU - Proietto, J.
AU - Shakib, S.
AU - Stuckey, Bronwyn
AU - Vath, J.E.
AU - Hughes, T.E.
PY - 2015
Y1 - 2015
N2 - © 2015 John Wiley & Sons Ltd. Aim: To assess the efficacy, safety and tolerability of beloranib treatment for obesity. Methods: This phase II, double-blind, randomized study investigated the effects of beloranib suspension (0.6, 1.2 and 2.4mg) or placebo, administered subcutaneously, for 12weeks in 147 participants (primarily white women) with obesity. No diet or exercise advice was administered. Results: At week 12, beloranib resulted in dose-dependent progressive weight loss of -5.5±0.5, -6.9±0.6 and -10.9±1.1kg for the 0.6, 1.2 and 2.4mg beloranib doses, respectively, compared with -0.4±0.4kg with placebo (all p
AB - © 2015 John Wiley & Sons Ltd. Aim: To assess the efficacy, safety and tolerability of beloranib treatment for obesity. Methods: This phase II, double-blind, randomized study investigated the effects of beloranib suspension (0.6, 1.2 and 2.4mg) or placebo, administered subcutaneously, for 12weeks in 147 participants (primarily white women) with obesity. No diet or exercise advice was administered. Results: At week 12, beloranib resulted in dose-dependent progressive weight loss of -5.5±0.5, -6.9±0.6 and -10.9±1.1kg for the 0.6, 1.2 and 2.4mg beloranib doses, respectively, compared with -0.4±0.4kg with placebo (all p
U2 - 10.1111/dom.12457
DO - 10.1111/dom.12457
M3 - Article
C2 - 25732625
SN - 1462-8902
VL - 17
SP - 566
EP - 572
JO - Diabetes, Obesity and Metabolism
JF - Diabetes, Obesity and Metabolism
IS - 6
ER -
